An organic compound can be applied as a host material for an OLED display device. The compound has a structure represented by Formula (I): ##STR00001## a and b, being independently 1, 2 or 3, respectively represent the numbers of electron donor D and electron acceptor A; c and d, independently being 0, 1, or 2, respectively representing the numbers of group L.sub.1 and group L.sub.2. D, L.sub.1 and L.sub.2 are each alkyl, cycloalkylene, heterocyclic group, aryl, heteroaryl, fused aryl, or fused heteroaryl; and A is selected from nitrogen-containing heterocyclic substituents, cyano-containing substituents, triaryl-boron-derived substituents, and phosphoxy-containing substituents. The compound has a D-(π)-σ-(π)-A structure with bipolarity, and the σ bond can interrupt an intramolecular charge transfer between D and A, so that the excited state is limited to a local excited state in moiety of D or A, and the compound has a small excited-state dipole moment.

The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting device comprising the same.

A rare earth compound including: one or a plurality of rare earth ions; and a ligand coordinated with the rare earth ion and having a condensed polycyclic aromatic group. At least part of the rare earth ions is a terbium(III) ion. The condensed polycyclic aromatic group is a residue formed by removing a hydrogen atom bonded to a condensed aromatic ring in formula (1) below from a condensed polycyclic aromatic compound represented by the following formula (1). Also disclosed is a luminescent body including the rare earth compound.

##STR00001##

The present invention relates to an organic electronic device and a compound comprised therein wherein the compound is represented by the Formula (I): HAr-L-Ar.sub.1—(—R.sup.1).sub.m.

The invention relates to an Organic light emitting diode comprising an anode electrode, a cathode electrode, at least one emission layer and an organic semiconductor layer, wherein the organic semiconductor layer is arranged between the anode electrode and the cathode electrode and the organic semiconductor layer comprises an alkali organic complex and a compound of formula 1 wherein X is selected from O, S or Se; and R.sup.1 and R.sup.2 are independently selected from the group consisting of C.sub.6 to C.sub.18 aryl group and C.sub.5 to C.sub.18 heteroaryl group, wherein each of R.sup.1 and R.sup.2 may independently be unsubstituted or substituted with at least one C.sub.1 to C.sub.12 alkyl group or C.sub.1 to C.sub.12 alkoxy group, preferably C.sub.1 to C.sub.4 alkyl group or C.sub.1 to C.sub.4 alkoxy group; and each R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are independently selected from the group consisting of H, C.sub.1 to C.sub.12 alkyl group or C.sub.1 to C.sub.12 alkoxy group, preferably H, C.sub.1 to C.sub.4 alkyl group or C.sub.1 to C.sub.4 alkoxy group; a method for preparing the same and the compound of Formula 1 comprised therein.

An acyl phosphine oxide initiator wherein the acyl group is selected from the group consisting of a benzoyl group substituted by an urea group or an oxalylamide group; a 2,6-dimethyl benzoyl group substituted in position 3 by an urea group or an oxalylamide group; a 2,6-dimethoxy benzoyl group substituted in position 3 by an urea group or an oxalylamide group; a 2,4,6-dimethyl benzoyl group substituted in position 3 by an urea group or an oxalylamide group; and a 2,4,6-trimethoxybenzoyl group substituted in position 3 by an urea group or an oxalylamide group.

The invention provides novel phosphorus imidazoquinoline amine derivatives, having agonistic activities to Toll-like receptors (TLRs), in particular TLR7 and/or TLR8, pharmaceutical compositions thereof, and methods of treatment, reduction or prevention of certain diseases or conditions mediated by or associated with TLR7 and/or TLR8, e.g., cancer, graft rejection, autoimmunity, inflammation allergy, asthma, infection, sepsis, and immunodeficiency.

The present invention relates to an electrically doped semiconducting material comprising at least one metallic element as n-dopant and at least one electron transport matrix compound comprising at least one phosphine oxide group, a process for its preparation, and an electronic device comprising the electrically doped semiconducting material.

The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

Disclosed is a system and method for Fmoc/tBu solution-phase peptide synthesis including the development of a new benzyl-type GAP protecting group, and related uses thereto. This novel GAP protecting group is utilized in place of a polymer support, facilitating C to N Fmoc peptide synthesis without chromatography, recrystallization, or polymer supports. The GAP group can be added and removed in high yield.